Analysis of Relationship between Serum lncRNA HIF1A-AS1,CXCL9 and Disease Severity,Adverse Pregnancy Outcomes in Patients with Preeclampsia
10.3969/j.issn.1671-7414.2024.06.012
- VernacularTitle:子痫前期患者血清lncRNA HIF1A-AS1,CXCL9水平表达与病情程度及不良妊娠结局的关系分析
- Author:
Jinhui ZHANG
1
;
Weiling LI
;
Lu YAN
Author Information
1. 西安高新医院妇产科,西安 710075
- Keywords:
preeclampsia;
lncRNA HIF1A-AS1;
CXCL9;
adverse pregnancy outcome
- From:
Journal of Modern Laboratory Medicine
2024;39(6):73-78,140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between serum long non-coding RNA hypoxia-inducible factor 1 alpha antisense RNA 1(lncRNA HIFA1-AS1),CXC chemokine ligand 9(CXCL9)and disease severity,adverse pregnancy outcome in patients with preeclampsia.Methods A total of 83 patients with preeclampsia admitted to Xi'an Gaoxin Hospital January 2021 to December 2022 were taken as preeclampsia group,According to the time of diagnosis,patients with preeclampsia were divided into early onset preeclampsia group(n=39)and late onset preeclampsia group(n=44).According to the severity of the condition,patients with preeclampsia were divided into two groups:mild preeclampsia group(n=51)and severe preeclampsia group(n=32).According to pregnancy outcomes,they were divided into a normal pregnancy outcome group(n=56)and an adverse pregnancy outcome group(n=27).At the same time,60 healthy pregnant women with pregnancy were collected as control group.Real-time fluorescence quantitative PC(qRT-PCR)was used to detect serum lncRNA HIF1A-AS1,and enzyme-linked immunosorbent assay(ELISA)was used to detect serum CXCL9.Spearman rank correlation analysis was used to analyze the association between serum lncRNA HIF1A-AS1,CXCL9 and severity of disease.Logistic regression analysis was used to analyze the factors influencing the adverse pregnancy outcome in patients with preeclampsia.ROC curve was drawn to assess the predictive value of serum lncRNA HIF1A-AS1,CXCL9 for adverse pregnancy outcome.Results The relative expression of serum lncRNA HIF1A-AS1(0.73±0.26)in preeclampsia group was lower than that(1.15±0.34)in control group,and CXCL9 level(209.34±45.34 pg/ml)higher than that(116.80±37.76 pg/ml)in control group,the differences were statistically significant(t=8.379,12.903,all P<0.05).The relative expression of serum lncRNA HIF1A-AS1(0.58±0.21)in early-onset preeclampsia group was lower than that in late-onset preeclampsia group(0.86±0.27),and CXCL9 level(236.60±31.02 pg/ml)higher than that in late-onset preeclampsia group(185.18±23.63 pg/ml),the differences were statistically significant(t=5.226,8.551,all P<0.05).The relative expression of serum lncRNA HIF1A-AS1(0.52±0.21)in severe preeclampsia group was lower than that in late-onset preeclampsia group(0.97±0.34),and CXCL9 level(253.38±41.20 pg/ml)higher than that in late-onset preeclampsia group(159.65±40.79 pg/ml),the differences were statistically significant(t=6.409,10.152,all P<0.05).Serum lncRNA HIF1A-AS1 and CXCL9 were associated with condition of preeclampsia(r=-0.627,0.651,all P<0.05).CXCL9[OR(95%CI):1.581(1.098～2.276)]was independent risk factor for adverse pregnancy outcome in patients with preeclampsia(P<0.05).LncRNA HIF1A-AS1[OR(95%CI):0.806(0.673～0.965)]was a protective factor(P<0.05),and early-onset preeclampsia[OR(95%CI):1.390(1.088～1.775)]and severe preeclampsia[OR(95%CI):1.589(1.222～2.066)]were risk factors for adverse pregnancy outcome(all P<0.05).Serum lncRNA HIF1A-AS1,CXCL9 and indicators combined had predictive value for adverse pregnancy outcome in patients with preeclampsia,with AUC of 0.770,0.767 and 0.876,respectively.And the combined prediction AUC was better than single indicator,and differences were statistically significant(Z=2.455,2.398,all P<0.05).Conclusion Serum lncRNA HIF1A-AS1 expression is down-regulated and CXCL9 expression is up-regulated in patients with preeclampsia,both indicators are associated with severity of disease and adverse pregnancy outcome.Early detection of two indicators are expected to be markers for predicting adverse pregnancy outcome in patients with preeclampsia.
